Gallium gozetotide not checked
Novartis · Ga-PSMA-11
FollowEvery change as it happens, and a Monday email
Trials
2 active
5 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Provided as PSMA-11 Kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide”In the company’s words, NCT05939414 on ClinicalTrials.gov
- Tested for
- Oligometastatic Prostate Cancer (OMPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).”In the company’s words, NCT05939414 on ClinicalTrials.gov
- Other names
- Ga-PSMA-11 · Locametz · Illuccix
Other drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- PasritamigJohnson & Johnson (Janssen) · Phase 3
- JNJ-87189401Johnson & Johnson (Janssen) · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- AAA617Novartis · Phase 2
- JSB462Novartis · Phase 2
- GedatolisibCelcuity Inc · Phase 1/2
Coming up1
- 25 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 17 NovStatus changed: Active, not recruiting to Terminated · ClinicalTrials.gov NCT06379217
- 17 NovCompletion date moved: 2026-10-09 to 2026-10-16 · ClinicalTrials.gov NCT06379217
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 25 Apr 2028 | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | |
| Phase 2Active, not recruiting | 2 Dec 2024 | A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer | |
| Phase 3Completed | 23 Nov 2023 | Study of Diagnostic Performance of [18F]CTT1057 in BCR | |
| Phase 1/2Withdrawn | 31 Mar 2030 | Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC | |
| Phase 1Terminated | 16 Oct 2026 | NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026